# Ponatinib for FLT3-ITD Acute Myelogenous Leukemia

> **NCT02428543** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Versailles Hospital** · enrollment: 49 (actual)

## Conditions studied

- Acute Myeloid Lukemia

## Interventions

- **DRUG:** Ponatinib and Cytarabine

## Key facts

- **NCT ID:** NCT02428543
- **Lead sponsor:** Versailles Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-07
- **Primary completion:** 2020-11
- **Final completion:** 2023-11
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2020-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02428543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02428543, "Ponatinib for FLT3-ITD Acute Myelogenous Leukemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02428543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*